Anti-DLL3 antibodies and drug conjugates for use in melanoma
AssigneeAbbvie Stemcentrx LLC
InventorsSamuel Williams, Laura Saunders, Kathryn A Loving
Life of this patent
Estimating the term…
Abstract
Anti-DLL3 antibodies and antibody drug conjugates for use in the diagnosis and treatment of melanoma.
Claims28
A method of treating melanoma in a subject, wherein the melanoma is characterized as having a DLL3 expression level above a threshold index value, the method comprising the step of administering to the subject an anti-DLL3 antibody drug conjugate, wherein the antibody drug conjugate comprises the formula M-[L-D]n wherein:
- M comprises an anti-DLL3 antibody comprising three CDRs of a light chain variable region amino acid sequence of SEQ ID NO:
- 405 and three CDRs of a heavy chain variable region amino acid sequence of SEQ ID NO:
- 407;
- L comprises a linker;
- D comprises a pyrrolobenzodiazepine (PBD);
- and
- n is an integer from 1 to 8.
A method of treating melanoma in a subject, wherein the melanoma is dacarbazine-refractory melanoma, vemurafenib-refractory melanoma, trametinib-refractory melanoma or dasatinib-refractory melanoma, the method comprising the step of administering to the subject an anti-DLL3 antibody drug conjugate, wherein the antibody drug conjugate comprises a humanized anti-DLL3 antibody conjugated to one or more pyrrolobenzodiazepines (PBDs), and wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 407.
A method of treating stage II melanoma in a subject, the method comprising the step of administering to the subject an anti-DLL3 antibody drug conjugate, wherein the antibody drug conjugate comprises a humanized anti-DLL3 antibody conjugated to one or more pyrrolobenzodiazepines (PBDs), wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 405 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO:
- 407;
- and wherein the PBD is PBD1:
Dependencies are inferred from the claim text.